# PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

> **NCT03013491** · PHASE1,PHASE2 · TERMINATED · sponsor: **CytomX Therapeutics** · enrollment: 196 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** CX-072
- **DRUG:** ipilimumab
- **DRUG:** vemurafenib

## Key facts

- **NCT ID:** NCT03013491
- **Lead sponsor:** CytomX Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-19
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 196 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013491, "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03013491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*